多核分析确定了人类结核病颗粒瘤中抑制性髓状细胞群
bioRxiv : the preprint server for biology
|March 31, 2025
概括
骨髓原抑制细胞 (MDSCs) 并不是结核病颗粒瘤中免疫抑制的主要驱动因素. 相反,表达树突细胞 (IDO1+ DCs) 的醇胺2,3二氧化酶-1在调节颗粒瘤内的免疫反应中起着关键作用.
科学领域:
- 免疫学 免疫学 免疫学
- 微生物学 微生物学
- 病原发生和发病的过程.
背景情况:
- 结核病 (TB) 是一个全球性的健康挑战,特别是多抗药性结核病 (MDR-TB).
- 主体导向疗法 (HDT) 正在探索,以增强免疫控制.
- 骨髓原抑制细胞 (MDSC) 被研究为MDR-TB的潜在HDT,但它们在结核病中的作用尚不清楚.
研究的目的:
- 调查MDSCs和其他髓质抑制体种群在结核病颗粒瘤微环境 (GME) 中的作用.
- 为了确定特定的髓质细胞子集是否有助于颗粒瘤内的免疫抑制.
主要方法:
- 从活跃结核病患者的84个颗粒瘤的空间转录造型和单细胞免疫型定型.
- 使用H&E染色方法对颗粒瘤进行组织学分类.
- 通过不同颗粒瘤成熟阶段和感兴趣的区域进行转录特征的比较.
主要成果:
- 颗粒瘤中的免疫抑制不是主要由经典的MDSCs驱动的.
- 印胺2,3二氧化酶-1表达树突细胞 (IDO1+ DCs) 是最常见的抑制性髓状细胞,特别是在细胞区域.
- IDO1+ DCs在空间上接近激活的T细胞,这表明局部免疫抑制.
- 不同阶段的颗粒瘤表现出不同的抑制性髓状细胞比例,影响进展.
- 高度的IDO1表达与复杂的免疫反应有关,包括抑制,激活和新陈代谢.
结论:
- 经典的MDSC在结核病颗粒瘤中起到较小的作用,与瘤微环境不同.
- IDO1+ DCs是结核病颗粒体内免疫抑制的关键调节者.
- 了解IDO1+抑制性髓状细胞对于开发新的结核病治疗点至关重要.
更多相关视频
07:42A Novel Microdissection Approach to Recovering Mycobacterium tuberculosis Specific Transcripts from Formalin Fixed Paraffin Embedded Lung Granulomas
Published on: June 5, 2014
8.0K
10:43Polarization of M1 and M2 Human Monocyte-Derived Cells and Analysis with Flow Cytometry upon Mycobacterium tuberculosis Infection
Published on: September 18, 2020
28.3K
相关概念视频
The Nucleolus
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
